Literature DB >> 18288967

Properdin and complement activation: a fresh perspective.

Dennis E Hourcade1.   

Abstract

The C3 convertases are the major proteases of the complement cascade and are assembled at the site of complement activation via several different pathways. Properdin's functional role in stabilizing the alternative pathway convertase has been long established; however, new evidence demonstrates that properdin can also bind to certain microbial surfaces, and provide a platform for de novo convertase assembly. Therefore, properdin participates in two distinct mechanisms for complement activation: the alternative pathway and a properdin-directed pathway. Previous work had implicated the alternative pathway in the initiation and/or progression of several autoimmune diseases and in the host defense against certain bacterial pathogens. Those conclusions were based on evidence that cannot distinguish effects of the alternative pathway from effects of the properdin-directed pathway. With the identification of the new role for properdin in C3 convertase assembly there became a pressing need to reassess the mechanisms of complement activation, determine the specific role of properdin in each of these pathways, and explore the new therapeutic avenues that could arise.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288967     DOI: 10.2174/138945008783502458

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  16 in total

1.  An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae.

Authors:  Sarika Agarwal; Viviana P Ferreira; Claudio Cortes; Michael K Pangburn; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

2.  Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury.

Authors:  Yuko Kimura; Lin Zhou; Takashi Miwa; Wen-Chao Song
Journal:  J Clin Invest       Date:  2010-10       Impact factor: 14.808

3.  Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia.

Authors:  Yoshiyasu Ueda; Takashi Miwa; Damodar Gullipalli; Sayaka Sato; Daisuke Ito; Hangsoo Kim; Matthew Palmer; Wen-Chao Song
Journal:  J Am Soc Nephrol       Date:  2018-06-01       Impact factor: 10.121

Review 4.  Complement regulators and inhibitory proteins.

Authors:  Peter F Zipfel; Christine Skerka
Journal:  Nat Rev Immunol       Date:  2009-09-04       Impact factor: 53.106

5.  Properdin binding to complement activating surfaces depends on initial C3b deposition.

Authors:  Morten Harboe; Christina Johnson; Stig Nymo; Karin Ekholt; Camilla Schjalm; Julie K Lindstad; Anne Pharo; Bernt Christian Hellerud; Kristina Nilsson Ekdahl; Tom Eirik Mollnes; Per H Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

6.  The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization.

Authors:  Bärbel Rohrer; Beth Coughlin; Kannan Kunchithapautham; Qin Long; Stephen Tomlinson; Kazue Takahashi; V Michael Holers
Journal:  Mol Immunol       Date:  2011-01-22       Impact factor: 4.407

7.  Xenotransplantation: Progress Along Paths Uncertain from Models to Application.

Authors:  Jeffrey L Platt; Marilia Cascalho; Jorge A Piedrahita
Journal:  ILAR J       Date:  2018-12-31

8.  Clinical and functional consequences of anti-properdin autoantibodies in patients with lupus nephritis.

Authors:  M Radanova; G Mihaylova; D Ivanova; M Daugan; V Lazarov; L Roumenina; V Vasilev
Journal:  Clin Exp Immunol       Date:  2020-05-07       Impact factor: 4.330

9.  Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.

Authors:  F Corvillo; M Bravo García-Morato; P Nozal; S Garrido; A Tortajada; S Rodríguez de Córdoba; M López-Trascasa
Journal:  Clin Exp Immunol       Date:  2016-01-22       Impact factor: 4.330

10.  The role of properdin in zymosan- and Escherichia coli-induced complement activation.

Authors:  Morten Harboe; Peter Garred; Julie K Lindstad; Anne Pharo; Fredrik Müller; Gregory L Stahl; John D Lambris; Tom E Mollnes
Journal:  J Immunol       Date:  2012-07-30       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.